Molecular Templates (MTEM) Competitors $0.0001 0.00 (-50.00%) As of 04/14/2025 10:24 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MTEM vs. AMGN, GILD, VRTX, REGN, ALNY, BIIB, UTHR, INCY, BMRN, and EXELShould you be buying Molecular Templates stock or one of its competitors? The main competitors of Molecular Templates include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), BioMarin Pharmaceutical (BMRN), and Exelixis (EXEL). These companies are all part of the "biotechnology" industry. Molecular Templates vs. Amgen Gilead Sciences Vertex Pharmaceuticals Regeneron Pharmaceuticals Alnylam Pharmaceuticals Biogen United Therapeutics Incyte BioMarin Pharmaceutical Exelixis Molecular Templates (NASDAQ:MTEM) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, community ranking, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment. Does the media refer more to MTEM or AMGN? In the previous week, Amgen had 76 more articles in the media than Molecular Templates. MarketBeat recorded 76 mentions for Amgen and 0 mentions for Molecular Templates. Amgen's average media sentiment score of 0.95 beat Molecular Templates' score of 0.00 indicating that Amgen is being referred to more favorably in the news media. Company Overall Sentiment Molecular Templates Neutral Amgen Positive Does the MarketBeat Community favor MTEM or AMGN? Amgen received 1211 more outperform votes than Molecular Templates when rated by MarketBeat users. Likewise, 71.83% of users gave Amgen an outperform vote while only 67.32% of users gave Molecular Templates an outperform vote. CompanyUnderperformOutperformMolecular TemplatesOutperform Votes34267.32% Underperform Votes16632.68% AmgenOutperform Votes155371.83% Underperform Votes60928.17% Is MTEM or AMGN more profitable? Amgen has a net margin of 12.24% compared to Molecular Templates' net margin of -61.35%. Amgen's return on equity of 176.32% beat Molecular Templates' return on equity.Company Net Margins Return on Equity Return on Assets Molecular Templates-61.35% -260.50% -46.90% Amgen 12.24%176.32%11.71% Which has higher valuation and earnings, MTEM or AMGN? Amgen has higher revenue and earnings than Molecular Templates. Molecular Templates is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMolecular Templates$23.48M0.00-$8.12M-$2.700.00Amgen$33.42B4.75$4.09B$7.5539.11 Which has more risk and volatility, MTEM or AMGN? Molecular Templates has a beta of 1.53, meaning that its share price is 53% more volatile than the S&P 500. Comparatively, Amgen has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500. Do analysts prefer MTEM or AMGN? Amgen has a consensus price target of $314.91, suggesting a potential upside of 6.64%. Given Amgen's stronger consensus rating and higher probable upside, analysts plainly believe Amgen is more favorable than Molecular Templates.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Molecular Templates 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Amgen 2 Sell rating(s) 9 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.48 Do institutionals and insiders believe in MTEM or AMGN? 95.5% of Molecular Templates shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 13.9% of Molecular Templates shares are held by company insiders. Comparatively, 0.7% of Amgen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummaryAmgen beats Molecular Templates on 16 of the 19 factors compared between the two stocks. Remove Ads Get Molecular Templates News Delivered to You Automatically Sign up to receive the latest news and ratings for MTEM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MTEM vs. The Competition Export to ExcelMetricMolecular TemplatesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1,000.00$6.33B$5.33B$7.57BDividend YieldN/A3.24%5.11%4.32%P/E Ratio0.006.7921.6617.82Price / Sales0.00225.97373.3994.61Price / CashN/A65.6738.1534.64Price / Book0.005.866.474.00Net Income-$8.12M$141.86M$3.20B$247.23M7 Day PerformanceN/A4.50%2.86%1.45%1 Month PerformanceN/A-12.65%-8.56%-6.24%1 Year PerformanceN/A-11.06%10.58%0.60% Molecular Templates Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MTEMMolecular TemplatesN/A$0.00-50.0%N/A-100.0%$1,000.00$23.48M0.00260Gap DownAMGNAmgen4.2708 of 5 stars$289.69-1.6%$314.04+8.4%+11.2%$155.62B$33.42B38.3728,000Analyst ForecastGILDGilead Sciences4.5435 of 5 stars$105.52-1.6%$105.12-0.4%+56.0%$133.54B$28.75B285.1917,000Positive NewsVRTXVertex Pharmaceuticals4.1 of 5 stars$474.560.0%$509.17+7.3%+26.0%$121.86B$11.02B-215.716,100Short Interest ↓Analyst RevisionPositive NewsHigh Trading VolumeREGNRegeneron Pharmaceuticals4.8717 of 5 stars$572.78-0.1%$966.88+68.8%-37.9%$62.62B$14.20B14.9611,900Analyst ForecastPositive NewsHigh Trading VolumeALNYAlnylam Pharmaceuticals4.5644 of 5 stars$232.95-1.2%$316.25+35.8%+56.4%$30.30B$2.25B-107.352,000BIIBBiogen4.698 of 5 stars$119.19-3.1%$213.33+79.0%-40.6%$17.45B$9.68B10.658,720Upcoming EarningsAnalyst RevisionUTHRUnited Therapeutics4.9024 of 5 stars$291.72-0.3%$388.25+33.1%+21.2%$13.10B$2.88B12.81980Insider TradePositive NewsINCYIncyte4.8639 of 5 stars$60.29-0.5%$74.88+24.2%+9.4%$11.67B$4.24B223.302,320BMRNBioMarin Pharmaceutical4.8867 of 5 stars$59.16-1.8%$94.00+58.9%-34.4%$11.29B$2.85B26.893,401Upcoming EarningsPositive NewsHigh Trading VolumeEXELExelixis4.2553 of 5 stars$34.84+0.8%$37.59+7.9%+61.0%$9.75B$2.17B19.681,220Positive NewsGap Down Remove Ads Related Companies and Tools Related Companies AMGN Competitors GILD Competitors VRTX Competitors REGN Competitors ALNY Competitors BIIB Competitors UTHR Competitors INCY Competitors BMRN Competitors EXEL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MTEM) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredRadical shift coming to the stock market (read this ASAP)This is an urgent warning for all American investors … In a matter of days, we could see a radical shift in...Weiss Ratings | SponsoredFirst look: The $3,500 iPhoneDid you hear that just before Trump's tariffs took effect, Apple sent five cargo planes packed with MacBooks a...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Molecular Templates, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Molecular Templates With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MTEM Stock Free MTEM Stock Alerts